Related Experiment Video

Updated: Jul 20, 2026

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

Breast screening in women aged 40-49 years

M H Seltzer, J H McDermott

    Lancet (London, England)
    |September 18, 1999
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
    11:49

    Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

    Published on: April 3, 2026

    A Study on an Intelligent Diagnosis and Treatment Assistant System for Acupuncture in Diminished Ovarian Reserve Based on a Knowledge Graph
    08:43

    A Study on an Intelligent Diagnosis and Treatment Assistant System for Acupuncture in Diminished Ovarian Reserve Based on a Knowledge Graph

    Published on: May 29, 2026

    Related Experiment Videos

    Last Updated: Jul 20, 2026

    Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
    08:56

    Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

    Published on: April 7, 2023

    Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
    11:49

    Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

    Published on: April 3, 2026

    A Study on an Intelligent Diagnosis and Treatment Assistant System for Acupuncture in Diminished Ovarian Reserve Based on a Knowledge Graph
    08:43

    A Study on an Intelligent Diagnosis and Treatment Assistant System for Acupuncture in Diminished Ovarian Reserve Based on a Knowledge Graph

    Published on: May 29, 2026

    Related Concept Videos

    Menopause01:28

    Menopause

    Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...

    Articles linked to this work by shared authors, journal, and citation graph.

    Enhanced community care for type 2 diabetes in Ireland: the patient's perspective on attending an integrated care centre.

    Irish medical journal·2025

    Pharmacogenomics: DPYD and Prevention of Toxicity.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2024

    A national survey of first line antibiotic use in neonatal units - and the potential scope for iatrogenic sensorineural hearing loss prevention.

    Frontiers in pediatrics·2024

    Central serous chorioretinopathy secondary to intramuscular testosterone therapy.

    Endocrinology, diabetes & metabolism case reports·2023

    A blockchain-based framework to support pharmacogenetic data sharing.

    The pharmacogenomics journal·2022

    Acute diabetic neuropathy following improved glycaemic control: a case series and review.

    Endocrinology, diabetes & metabolism case reports·2020

    [177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

    Lancet (London, England)·2026

    Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial.

    Lancet (London, England)·2026

    Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

    Lancet (London, England)·2026

    Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

    Lancet (London, England)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us